The immunotherapy reduces treatment burden by making it accessible at approximately 1/4th
cost of the reference drug
The treatment is likely to benefit more than 5 lakh patients
Mumbai: Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”), an
innovation-led life-sciences company with an international presence has launched the world’s first
biosimilar of Nivolumab in India under the brand name Tishtha™, reinforcing the company’s growing
capability in advanced biologics and Immuno-Oncology. Tishtha™ will be available in 100 mg and 40 mg
dosages priced at ₹28,950 and ₹13,950 respectively. The prices are approximately 1/4th of the reference
drug. This will improve affordability and reduce the overall treatment burden for patients.
The twostrength portfolio enables oncologists to optimise dosing and minimise wastage – a key driver of treatment
economics in immunotherapy.
Speaking on the development, Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Ltd., said,
“At Zydus, we believe every patient deserves timely access to affordable, advanced cancer care. With the
launch of Tishtha™, we are expanding access to Immuno-Oncology through a patient-centric therapy. Our
aim is to support patients with consistent care throughout their treatment journey. We remain committed
to improving patient access to high-quality biosimilar immunotherapies.”
Access to modern treatment is determined by three critical factors: consistency, affordability, and reach.
Reliable availability of checkpoint inhibitors** is essential for cancer patients who require therapy over
multiple cycles, as interruptions may add both clinical and financial stress for families. Developed and
manufactured in India, Tishtha™ ensures long-term dependability for patients throughout their treatment
journey. For patients living with cancer, sustained and predictable access to therapy is critical. By
introducing Tishtha™ in India, Zydus expands access to advanced Immuno-Oncology treatment.
0 Comments